应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BK4139 生物科技
未开盘 01-02 16:00:00 EST
1,118.93
+1.37
+0.12%
最高
1,122.48
最低
1,110.42
成交量
7.53亿
今开
1,117.56
昨收
1,117.56
日振幅
1.08%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
121.94亿
换手率
--
流通股本
0.00
市净率
7.110658
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Crinetics Pharmaceuticals将公布Palsonify业务进展及Atumelnant治疗先天性肾上腺皮质增生症二期试验第四队列顶线结果
美股速递 · 05:00
Crinetics Pharmaceuticals将公布Palsonify业务进展及Atumelnant治疗先天性肾上腺皮质增生症二期试验第四队列顶线结果
Mineralys Therapeutics:靶向醛固酮,重塑心肾代谢疾病治疗格局
药研前瞻 · 01-04 19:29
Mineralys Therapeutics:靶向醛固酮,重塑心肾代谢疾病治疗格局
国家林草种质资源雄安库年底建成,首批“藏品”来头不小
北京日报客户端 · 01-04 15:57
国家林草种质资源雄安库年底建成,首批“藏品”来头不小
Karyopharm Therapeutics公布依据纳斯达克上市规则5635(C)(4)授予的引援股权奖励
投资观察 · 01-03 06:25
Karyopharm Therapeutics公布依据纳斯达克上市规则5635(C)(4)授予的引援股权奖励
Zura Bio有限公司于12月29日签署多项协议,SEC文件确认其商业优势显著提升
美股速递 · 01-03 05:29
Zura Bio有限公司于12月29日签署多项协议,SEC文件确认其商业优势显著提升
Psyence Biomedical Ltd.盘中异动 大幅上涨6.05%
市场透视 · 01-03 05:00
Psyence Biomedical Ltd.盘中异动 大幅上涨6.05%
Prothena Corporation Plc盘中异动 股价大跌5.03%
市场透视 · 01-03 04:01
Prothena Corporation Plc盘中异动 股价大跌5.03%
Inhibrx Biosciences, Inc.盘中异动 下午盘股价大跌5.04%
市场透视 · 01-03 04:01
Inhibrx Biosciences, Inc.盘中异动 下午盘股价大跌5.04%
Azitra Inc盘中异动 股价大涨5.51%
市场透视 · 01-02 23:32
Azitra Inc盘中异动 股价大涨5.51%
Gossamer Bio, Inc.盘中异动 早盘股价大跌5.03%报2.94美元
市场透视 · 01-02 23:08
Gossamer Bio, Inc.盘中异动 早盘股价大跌5.03%报2.94美元
Cibus, Inc.盘中异动 早盘股价大涨5.17%报1.83美元
市场透视 · 01-02 22:57
Cibus, Inc.盘中异动 早盘股价大涨5.17%报1.83美元
美国OTC市场Opthea Limited盘中异动 股价大涨140.84%
市场透视 · 01-02 22:46
美国OTC市场Opthea Limited盘中异动 股价大涨140.84%
Maia Biotechnology, Inc.盘中异动 早盘急速上涨5.21%报1.61美元
市场透视 · 01-02 22:42
Maia Biotechnology, Inc.盘中异动 早盘急速上涨5.21%报1.61美元
Regenxbio Inc.盘中异动 早盘股价大跌5.97%
市场透视 · 01-02 22:35
Regenxbio Inc.盘中异动 早盘股价大跌5.97%
Eledon Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.30%报1.59美元
市场透视 · 01-02 22:30
Eledon Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.30%报1.59美元
英国MHRA批准Zapomeran(Kostaive)mRNA新冠疫苗用于18岁及以上人群免疫接种
美股速递 · 01-02 21:41
英国MHRA批准Zapomeran(Kostaive)mRNA新冠疫苗用于18岁及以上人群免疫接种
MeiraGTx Holdings Plc与Perceptive生命科学主基金签订股份购买协议 - 美国证券交易委员会文件披露
美股速递 · 01-02 21:06
MeiraGTx Holdings Plc与Perceptive生命科学主基金签订股份购买协议 - 美国证券交易委员会文件披露
艾伯维12亿美元押注三抗TCE,与泽璟达成合作和授权协议
Minhua笔记 · 01-01
艾伯维12亿美元押注三抗TCE,与泽璟达成合作和授权协议
Outlook Therapeutics公司:FDA尚未明确何种验证性证据可被接受
美股速递 · 01-01
Outlook Therapeutics公司:FDA尚未明确何种验证性证据可被接受
Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™(贝伐珠单抗-Vikg)审评的最新监管进展
美股速递 · 01-01
Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™(贝伐珠单抗-Vikg)审评的最新监管进展
加载更多
公司概况
公司名称:
生物科技
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1118.931,"timestamp":1767387599999,"preClose":1117.5642,"halted":0,"volume":753231826,"delay":0,"changeRate":0.001223,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":1.366821,"latestTime":"01-02 16:00:00 EST","open":1117.5638,"high":1122.4816,"low":1110.422,"amount":12194063976.708084,"amplitude":0.010791,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767623400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.110658,"peRate":-127.91266,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1133602751","title":"Crinetics Pharmaceuticals将公布Palsonify业务进展及Atumelnant治疗先天性肾上腺皮质增生症二期试验第四队列顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133602751","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133602751?lang=zh_cn&edition=full","pubTime":"2026-01-05 05:00","pubTimestamp":1767560414,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. (CRNX) 即将披露其Palsonify项目的战略发展动态,并同步公开Atumelnant针对先天性肾上腺皮质增生症(CAH)开展的二期临床试验中第四患者队列的顶线研究数据。此次更新将涵盖该创新疗法的临床进展与企业商业布局的双重维度,为市场提供关键研发里程碑的最新洞察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRNX","BK4007"],"gpt_icon":0},{"id":"2600235940","title":"Mineralys Therapeutics:靶向醛固酮,重塑心肾代谢疾病治疗格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2600235940","media":"药研前瞻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600235940?lang=zh_cn&edition=full","pubTime":"2026-01-04 19:29","pubTimestamp":1767526153,"startTime":"0","endTime":"0","summary":"摘要Mineralys Therapeutics 是一家临床阶段的生物制药公司,其全部战略核心与未来价值均寄托于一款名为Lorundrostat的口服、高选择性醛固酮合成酶抑制剂。Mineralys的创新逻辑建立在一个明确的医学认知上:醛固酮失调是多种心肾疾病共同的关键病理驱动因子。同时,高血压及其他CRMS疾病会导致过早发病和死亡,二者相互影响,形成恶性循环。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104205556a6f1f943&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104205556a6f1f943&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","MLYS","BK4539"],"gpt_icon":0},{"id":"2600746041","title":"国家林草种质资源雄安库年底建成,首批“藏品”来头不小","url":"https://stock-news.laohu8.com/highlight/detail?id=2600746041","media":"北京日报客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600746041?lang=zh_cn&edition=full","pubTime":"2026-01-04 15:57","pubTimestamp":1767513420,"startTime":"0","endTime":"0","summary":"转自:北京日报客户端国家林草种质资源设施保存库(雄安)预计今年年底,国家林草种质资源设施保存库(雄安)项目建成,2028年将投用,规划收集和长期保存180万份重要林草种质资源。北京林业大学国家林草种质库管运中心一开年就发布新进展,首批林草种质凭证标本已完成采集,存放在该校博物馆,待雄安库建成后将全部入库。首批“藏品”来头不小,包括雪山杜鹃、紫茎、瘿椒树等重要珍稀濒危植物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-04/doc-inhfcphs7567386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4109","BK4121","DNA"],"gpt_icon":0},{"id":"1149622364","title":"Karyopharm Therapeutics公布依据纳斯达克上市规则5635(C)(4)授予的引援股权奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1149622364","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149622364?lang=zh_cn&edition=full","pubTime":"2026-01-03 06:25","pubTimestamp":1767392727,"startTime":"0","endTime":"0","summary":"1月2日——Karyopharm Therapeutics Inc宣布,公司已根据纳斯达克上市规则5635(C)(4)条款,向新入职员工授予了引援性股权激励。该举措旨在吸引高端人才加入企业团队,通过股权授予方式强化人才与企业发展的深度绑定。此次股权授予完全遵循纳斯达克相关监管要求,体现了公司治理的规范性与透明度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"gpt_icon":0},{"id":"1178014392","title":"Zura Bio有限公司于12月29日签署多项协议,SEC文件确认其商业优势显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1178014392","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178014392?lang=zh_cn&edition=full","pubTime":"2026-01-03 05:29","pubTimestamp":1767389350,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会文件披露,Zura Bio有限公司在12月29日与多个合作单元达成系列战略性协议。经专业评估,这些协议被确认将为公司创造更优越的商业价值与市场竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2600094093","title":"Psyence Biomedical Ltd.盘中异动 大幅上涨6.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600094093","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600094093?lang=zh_cn&edition=full","pubTime":"2026-01-03 05:00","pubTimestamp":1767387611,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日05时00分,Psyence Biomedical Ltd.股票出现波动,股价大幅上涨6.05%。截至发稿,该股报0.799美元/股,成交量21.1463万股,换手率11.30%,振幅8.56%。Psyence Biomedical Ltd.股票所在的生物技术行业中,整体涨幅为0.09%。Psyence Biomedical Ltd.公司简介:Psyence Biomedical Ltd是一家生命科学生物技术公司,致力于开拓在心理健康和福祉领域中使用天然致幻剂的应用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103050011a6ec9632&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103050011a6ec9632&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2600801503","title":"Prothena Corporation Plc盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600801503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600801503?lang=zh_cn&edition=full","pubTime":"2026-01-03 04:01","pubTimestamp":1767384077,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日04时01分,Prothena Corporation Plc股票出现波动,股价快速跳水5.03%。截至发稿,该股报9.07美元/股,成交量31.6116万股,换手率0.59%,振幅6.28%。Prothena Corporation Plc股票所在的生物技术行业中,整体跌幅为0.08%。Prothena Corporation Plc公司简介:Prothena Corp PLC是一家临床生物技术公司,专注于蛋白质失调和具有改变破坏性神经退行性疾病以及罕见和周围淀粉样蛋白疾病进程潜力的研究性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040117a4957efc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040117a4957efc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4104","IE0034390439.USD","AL","BK4572","LU1169589451.USD","PRTA","IE00B19Z6F94.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2600018204","title":"Inhibrx Biosciences, Inc.盘中异动 下午盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600018204","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600018204?lang=zh_cn&edition=full","pubTime":"2026-01-03 04:01","pubTimestamp":1767384069,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日04时01分,Inhibrx Biosciences, Inc.股票出现波动,股价急速下挫5.04%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.08%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040109a4957eea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040109a4957eea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2600064846","title":"Azitra Inc盘中异动 股价大涨5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600064846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600064846?lang=zh_cn&edition=full","pubTime":"2026-01-02 23:32","pubTimestamp":1767367958,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日23时32分,Azitra Inc股票出现异动,股价快速上涨5.51%。Azitra Inc股票所在的生物技术行业中,整体涨幅为0.35%。Azitra Inc公司简介:Anitra Inc 是一家早期临床生物制药公司,专注于使用工程蛋白质和活体生物治疗产品开发精准皮肤病学疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010223323897a0f423&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010223323897a0f423&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2600609754","title":"Gossamer Bio, Inc.盘中异动 早盘股价大跌5.03%报2.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600609754","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600609754?lang=zh_cn&edition=full","pubTime":"2026-01-02 23:08","pubTimestamp":1767366510,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日23时08分,Gossamer Bio, Inc.股票出现波动,股价急速下跌5.03%。Gossamer Bio, Inc.股票所在的生物技术行业中,整体涨幅为0.50%。其相关个股中,Jasper Therapeutics Inc C/Wts 24/09/2026 、Pepgen Inc.、Geovax Labs, Inc.涨幅较大,Can Fite Biopharma Ltd、Outlook Therapeutics, Inc.、Sensei Biotherapeutics, Inc.较为活跃,换手率分别为82.97%、54.56%、52.39%,振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Psyence Biomedical Ltd C/Wts 25/01/2029、Humacyte Inc C/Wts 27/08/2026 ,振幅分别为45.14%、34.51%、21.34%。Gossamer Bio, Inc.公司简介:Gossamer Bio Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102230830a6ebfbba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102230830a6ebfbba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","GOSS","BK4139"],"gpt_icon":0},{"id":"2600617750","title":"Cibus, Inc.盘中异动 早盘股价大涨5.17%报1.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600617750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600617750?lang=zh_cn&edition=full","pubTime":"2026-01-02 22:57","pubTimestamp":1767365860,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日22时57分,Cibus, Inc.股票出现波动,股价大幅拉升5.17%。截至发稿,该股报1.83美元/股,成交量5.2462万股,换手率0.10%,振幅7.43%。Cibus, Inc.股票所在的生物技术行业中,整体涨幅为0.40%。Cibus, Inc.公司简介:Cibus Inc 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102225740953bea9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102225740953bea9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBUS","BK4139"],"gpt_icon":0},{"id":"2600097890","title":"美国OTC市场Opthea Limited盘中异动 股价大涨140.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600097890","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600097890?lang=zh_cn&edition=full","pubTime":"2026-01-02 22:46","pubTimestamp":1767365197,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日22时46分,美国OTC市场Opthea Limited股票出现异动,股价大幅拉升140.84%。截至发稿,该股报0.057美元/股,成交量100股,换手率0.00%,振幅0.00%。美国OTC市场Opthea Limited股票所在的生物技术行业中,整体跌幅为0.24%。美国OTC市场Opthea Limited公司简介:Opthea Ltd致力于研发针对血管内皮生长因子 C、D和R3的新型治疗产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102224637a6ebf0d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102224637a6ebf0d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OPTEY","CKDXF"],"gpt_icon":0},{"id":"2600013567","title":"Maia Biotechnology, Inc.盘中异动 早盘急速上涨5.21%报1.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600013567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600013567?lang=zh_cn&edition=full","pubTime":"2026-01-02 22:42","pubTimestamp":1767364936,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日22时42分,Maia Biotechnology, Inc.股票出现波动,股价急速拉升5.21%。Maia Biotechnology, Inc.股票所在的生物技术行业中,整体跌幅为0.23%。其相关个股中,Jasper Therapeutics Inc C/Wts 24/09/2026 、Sellas Life Sciences Group, Inc.、Opus Genetics, Inc.涨幅较大,Sensei Biotherapeutics, Inc.、Can Fite Biopharma Ltd、Outlook Therapeutics, Inc.较为活跃,换手率分别为48.70%、46.20%、30.90%,振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Psyence Biomedical Ltd C/Wts 25/01/2029、Genenta Science Spa,振幅分别为38.40%、34.51%、19.46%。Maia Biotechnology, Inc.公司简介:MAIA Biotechnology Inc 是一家临床阶段的生物制药公司,致力于开发针对癌症的靶向免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010222421697a0f398&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010222421697a0f398&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2600013838","title":"Regenxbio Inc.盘中异动 早盘股价大跌5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600013838","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600013838?lang=zh_cn&edition=full","pubTime":"2026-01-02 22:35","pubTimestamp":1767364508,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日22时35分,Regenxbio Inc.股票出现异动,股价急速跳水5.97%。截至发稿,该股报13.54美元/股,成交量4.7624万股,换手率0.09%,振幅5.38%。Regenxbio Inc.股票所在的生物技术行业中,整体跌幅为0.13%。Regenxbio Inc.公司简介:Regenxbio Inc 是一家生物技术公司。Regenxbio 平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102223508a494ed46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102223508a494ed46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BK4563","RGNX"],"gpt_icon":0},{"id":"2600089091","title":"Eledon Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.30%报1.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600089091","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600089091?lang=zh_cn&edition=full","pubTime":"2026-01-02 22:30","pubTimestamp":1767364229,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日22时30分,Eledon Pharmaceuticals, Inc.股票出现波动,股价大幅上涨5.30%。Eledon Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。其相关个股中,Psyence Biomedical Ltd C/Wts 25/01/2029、Genenta Science Spa、Sellas Life Sciences Group, Inc.涨幅较大,Sensei Biotherapeutics, Inc.、Can Fite Biopharma Ltd、Outlook Therapeutics, Inc.较为活跃,换手率分别为45.77%、35.36%、18.44%,振幅较大的相关个股有Geovax Labs, Inc.、Moolec Science Sa、Mereo Biopharma Group Plc,振幅分别为6.84%、5.97%、5.59%。Eledon Pharmaceuticals, Inc.公司简介:Eledon Pharmaceuticals Inc 是一家处于临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102223029a6ebe844&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102223029a6ebe844&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELDN","BK4139"],"gpt_icon":0},{"id":"1173114596","title":"英国MHRA批准Zapomeran(Kostaive)mRNA新冠疫苗用于18岁及以上人群免疫接种","url":"https://stock-news.laohu8.com/highlight/detail?id=1173114596","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173114596?lang=zh_cn&edition=full","pubTime":"2026-01-02 21:41","pubTimestamp":1767361267,"startTime":"0","endTime":"0","summary":"英国药品和保健品监管局已正式批准ZapomeranmRNA新冠疫苗的紧急使用授权,该疫苗获准用于18岁及以上成年人群的主动免疫接种。此次批准标志着基于mRNA技术的新冠疫苗阵营再添重要力量,为应对持续演变的疫情提供了新的防控工具。作为由Arcturus Therapeutics Ltd.研发的创新型疫苗,Zapomeran采用自扩增mRNA技术平台,具有单剂接种可能诱发强效免疫应答的潜力。此次获批将扩大英国疫苗接种计划的可选范围,为不同健康需求的成年人群提供更多免疫策略选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"1176425366","title":"MeiraGTx Holdings Plc与Perceptive生命科学主基金签订股份购买协议 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1176425366","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176425366?lang=zh_cn&edition=full","pubTime":"2026-01-02 21:06","pubTimestamp":1767359188,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会(SEC)最新文件显示,MeiraGTx Holdings Plc已与Perceptive生命科学主基金正式签署股份购买协议。该协议标志着双方在资本层面的重要合作迈出实质性步伐。\n此次股份购买协议的签订,预计将为MeiraGTx Holdings Plc带来新的资金支持,助力其推进基因治疗领域的研发进程。作为一家专注于开发变革性基因疗法的生物技术公司,MeiraGTx通过此次与专业医疗健康投资机构的合作,有望进一步巩固其在行业内的竞争优势。\n协议具体条款及交易细节已在SEC备案文件中完整披露。市场关注此次股权交易将对公司未来发展产生的战略影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"gpt_icon":0},{"id":"2600118059","title":"艾伯维12亿美元押注三抗TCE,与泽璟达成合作和授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2600118059","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600118059?lang=zh_cn&edition=full","pubTime":"2026-01-01 15:22","pubTimestamp":1767252148,"startTime":"0","endTime":"0","summary":"艾伯维正通过一项可能高达12亿美元的交易,进一步拓展其在肿瘤免疫治疗领域的布局。该交易包括向泽璟支付1亿美元的首付款,以及高达6000万美元的近期临床和选择权相关款项。艾伯维在2025年通过两项以三特异性抗体为核心的交易,进一步丰富了其肿瘤产品线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101154040a6e831da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260101154040a6e831da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0211327993.USD","IE00B42XCP33.USD","LU2347655156.SGD","BK4559","IE00B19Z3B42.SGD","LU0795875086.SGD","LU0965509283.SGD","LU0820561909.HKD","LU2237443549.SGD","LU2089984988.USD","IE0004445239.USD","IE0002270589.USD","IE00B2B36J28.USD","IE00B19Z3581.USD","BK4139","LU0058720904.USD","LU0310799852.SGD","LU1267930490.SGD","LU1244550494.USD","IE00BLSP4239.USD","LU0661504455.SGD","LU1093756168.USD","LU1585245621.USD","SG9999015945.SGD","LU1934455277.USD","LU2237443895.HKD","SG9999011175.SGD","LU2129689431.USD","LU2089284900.SGD","LU0965509010.AUD","LU1934455194.USD","BK4550","LU0738911758.USD","SG9999015986.USD","SG9999003800.SGD","LU1989772923.USD","LU1732800096.USD","LU0432979614.USD","IE00B4R5TH58.HKD","LU1057294990.SGD","LU1718418525.SGD","LU1496350502.SGD","LU0965509101.SGD","LU0320765646.SGD","LU0256863902.USD","LU1732799900.SGD","LU1989772840.SGD","LU2112291526.USD","ABBV","LU0158827948.USD"],"gpt_icon":0},{"id":"1195317623","title":"Outlook Therapeutics公司:FDA尚未明确何种验证性证据可被接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1195317623","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195317623?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:17","pubTimestamp":1767215830,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics公司近日面临监管不确定性,美国食品药品监督管理局(FDA)至今未就公司提交的药品申请给出明确指引。监管机构尚未表态何种类型的验证性临床证据能够满足审批要求,这为该公司核心产品的上市路径增添了变数。\n当前局面反映出生物科技企业在创新药审评过程中常见的挑战。FDA的沉默意味着Outlook Therapeutics需要继续投入资源探索符合监管要求的证据体系,而这一过程可能影响产品商业化的时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"1145824968","title":"Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™(贝伐珠单抗-Vikg)审评的最新监管进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1145824968","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145824968?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:16","pubTimestamp":1767215790,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc. (OTLK) 近日披露了旗下核心产品Ons-5010/Lytenava™(贝伐珠单抗-Vikg)针对湿性年龄相关性黄斑变性(湿性AMD)适应症的最新监管动态。该公司已接获美国食品药品监督管理局(FDA)就该项新药申请(BLA)的审评更新通知,标志着该疗法在美获批进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}